lunes, 8 de diciembre de 2014

WHO Pharmaceuticals Newsletter No.6, 2014



OMS, 5 de diciembre de 2014

Contenido

Regulatory Matters

Agomelatine ................................................................................................ 4

Azithromycin ............................................................................................... 4

Basiliximab.................................................................................................. 4

Clopidogrel .................................................................................................. 5

Colistin, colistimethate sodium (known as polymyxins) .............................. 5

Colobreathe® (colistimethate sodium dry powder for inhalation) ............... 6

Denosumab ................................................................................................. 7

Immunoglobulins ......................................................................................... 7

Ponatinib .................................................................................................... 8

Rituximab ................................................................................................... 8

Sulfamethoxazole-trimethoprim ..................................................................... 9

Zopiclone .................................................................................................... 9


Safety of medicines

Amitriptyline............................................................................................... 11

Boceprevir and telaprevir ............................................................................. 11

Interferon beta ........................................................................................... 11

Zoledronic acid ........................................................................................... 11


Signal

Agomelatine and thrombocytopenia ............................................................... 13

Dronedarone and ventricular arrhythmia ........................................................ 18

Dronedarone and vision abnormal ................................................................. 28


Feature

16th International Conference of Drug Regulatory Authorities (ICDRA)

and its recommendations ............................................................................. 36


Número completo disponible en http://bit.ly/1yUGlUj